Klaria Interim Report Q3 2026

Klaria Interim Report 1 July - 30 September 2026

Summary of the interim report

Third quarter of 2026

The group in total

- Net sales 0.0 MSEK (0.0 MSEK)

- Other income 0.0 MSEK (0.0 MSEK)

- R&D expenses for the quarter amounted to 1.6 MSEK (4.8 MSEK)

- Profit after tax amounted to -6.5 MSEK (-8.7 MSEK)

- Earnings per share for the quarter amounted to -0.03 SEK (-0.07 SEK)

- Cash flow from operating activities amounted to -5.3 MSEK (-31.2 MSEK)

- Liquid assets on the balance sheet date amounted to 6.1 MSEK (2.5 MSEK)

- Group equity as of september 30 amounted to -40.1 MSEK (4.5 MSEK)

- Equity in the parent company as of September 30 amounted to 77.3 MSEK (94.5 MSEK)

The period January-September 2026

The group in total

- Net sales 0.1 MSEK (9.0 MSEK)

- Other income 0.0 MSEK (0.0 MSEK)

- R&D expenses for the quarter amounted to 10.9 MSEK (15.3 MSEK)

- Profit after tax amounted to -28.1 MSEK (-30.4 MSEK)

- Earnings per share for the period amounted to -0.11 SEK (-0.18 SEK)

- Cash flow from operating activities amounted to -20.2 MSEK (-32.6 MSEK)

This interim report has been prepared for the group in accordan ce with IAS 34 Interim Reporting and the Annual Accounts Act (ÅR L) as well as IFRS, as adopted by the EU. For the

parent company, the Annual Accounts Act (ÅRL) and the Council for Financial Reporting Recommendation RFR 2 Accounting for legal entities have been applied.

For more information, visit the Klaria Pharma Holding website klaria.com or contact:

Fredrik Hübinette, Chairman of the Board of Directors
info@klaria.com
Tel: +46 (0) 8-446 42 99

This is Klaria Pharma Holding AB

Klaria (Klaria Pharma Holding AB) is a Swedish listed pharmaceutical company that develops innovative, rapid-acting products. By combining patented technology of a film that attaches to the oral mucosa and well proven pharmaceuticals, the company has developed a drug distribution concept with many benefits and potential uses. Klaria is listed on Nasdaq First North Growth Markets under the short name KLAR. FNCA Sweden is Certified Advisor (info@fnca.se, +46(0) 8-528 00 399) for Klaria Pharma Holding AB. For more information, see www.klaria.com.